/ / /
Dave joins Gurnet Point Capital with over 20 years of Operational and Executive Management experience in both Pharma and Biotech. Most recently, Dave joined GPC in early 2020 from Roivant Sciences, a biopharmaceutical drug development company, where he served as Chief Executive Officer of one of its infectious diseases businesses.
>Prior to his role at Roivant, Dave was Senior Vice President, Commercial, at Novo Nordisk US, where he led the successful transformation of the company’s commercial operating model into a purely integrated sales and marketing organization. He led the company through multiple new product launches, including one of the most successful launches in Type 2 Diabetes to-date.
Dave began his career at Ortho-McNeil, a Johnson & Johnson Company business, as a sales representative, progressing through key commercial management roles, including market access, sales leadership, marketing and new product development in a wide variety of therapeutic areas. He later was named Group Marketing Director at Janssen Pharmaceuticals, another Johnson & Johnson business, before making the transition to biotech and taking the position of VP Global Commercial Operations and later Chief Business Officer at Tranzyme Pharma, where, among other responsibilities, he drove the pre-launch of the company’s primary asset. In 2013, he was named Chief Commercial Officer (and latterly also President) at biotech company, Cempra Pharmaceuticals, where he transformed the organization from development stage to commercial ready.